ラマト・ガンで最高のPET-MRI検査医師 - トップ10名の医師

Prof. Amos Toren

MD, PhD, MHA | Pediatric Hemato-Oncology & Bone Marrow Transplant Specialist

Department:

Pediatric Hemato-Oncology & BMT Division, Sheba Medical Center

Languages:

Hebrew, English

Professional Summary

Inside Sheba’s Hematology Ecosystem: Expertise Recognized by Forbes Israel

Prof. Amos Toren is a highly experienced pediatric hemato-oncologist and former Director of the Pediatric Hemato-Oncology and Bone Marrow Transplant Division at Sheba Medical Center. He is board-certified in pediatrics, general hematology, and pediatric hemato-oncology, with additional academic qualifications in genetics and healthcare management.

Prof. Toren is internationally recognized for his work in advanced therapies for pediatric cancers, particularly in the fields of immunotherapy and bone marrow transplantation. His clinical approach combines cutting-edge research with individualized treatment strategies for complex and high-risk cases.

Areas of Expertise

Pediatric oncology and hematologic malignancies

Leukemia and lymphoma in children and young adults

Bone marrow and stem cell transplantation

Immune deficiencies and chronic blood disorders

Treatment of rare and complex pediatric cancers

Advanced cellular therapies (including CAR T-cell approaches)

Education & Academic Background

MD, Faculty of Medicine, Tel Aviv University, Israel

Residency in Pediatrics, Sheba Medical Center

Residency in Hematology, Sheba Medical Center

Specialization in Pediatric Hemato-Oncology and Bone Marrow Transplantation, Hadassah Medical Center

PhD in Human Genetics, Tel Aviv University

Master of Health Administration (MHA), Recanati Business School, Tel Aviv University

Clinical & Research Experience

Prof. Toren has led one of Israel’s most advanced pediatric oncology and transplantation programs, treating both children and young adults (up to age 30) with complex malignancies.

His research focuses on:

CAR T-cell therapy for relapsed and resistant leukemias and lymphomas

cellular immunotherapy approaches (including cytokine-induced killer cells)

pediatric brain tumors

innovative targeted treatments in pediatric oncology

He is actively involved in translational research aimed at improving outcomes in treatment-resistant cancers.

International Collaboration

The department led by Prof. Toren maintains strong collaborations with leading global institutions, including:

St. Anna Children’s Hospital (Austria)

National Cancer Institute (NIH), USA

St. Jude Children’s Research Hospital, USA

Academic & Professional Roles

Former Director, Pediatric Hemato-Oncology & BMT Division

Former Head of Hematology Division, Tel Aviv University (two terms)

Member of leading international societies:

American Society of Hematology (ASH)

Children’s Oncology Group (COG)

European Society of Pediatric Hematology (ESPHI)

European Group for Blood and Marrow Transplantation (EBMT)

Center for International Blood and Marrow Transplant Research (CIBMTR)

Member, Israeli Ministry of Health Cord Blood Committee

Board Certifications

Pediatrics

Pediatric Hemato-Oncology

Bone Marrow Transplantation

Selected Publications

Immunoglobulin prophylaxis in pediatric stem cell transplantation

Overcoming resistance to PARP inhibitors in cancer therapy

Additional peer-reviewed publications in pediatric oncology and hematology

Why Patients Choose Prof. Toren

Extensive experience in complex pediatric oncology and transplantation

Expertise in advanced immunotherapies (including CAR T-cell approaches)

Strong integration of research and clinical practice

Leadership in a Top-10 globally ranked hospital

Experience with rare and treatment-resistant cases

Dr. Almog Ben-Yaacov is an Attending Surgeon in the Department of General and Oncological Surgery (Surgery C) at Sheba Medical Center. He specializes in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). His clinical focus includes gastric cancer, sarcoma, and complex colorectal malignancies. Since 2018, he has performed more than 200 HIPEC procedures.

MD, Semmelweis University, 2006, with honors. Training in cardiothoracic surgery at Sheba Medical Center. Residency in general surgery at Montefiore (Albert Einstein) and at Rabin (Beilinson). Board-certified in General Surgery and in Surgical Oncology.

Advanced training includes ESSO-certified HIPEC in Hamburg. Microwave liver ablation in Reims. NanoKnife at King’s College London. Advanced surgical oncology at Memorial Sloan Kettering (2019). His publications cover CRS+HIPEC outcomes and Hartmann’s reversal.

Prof. Amit Tirosh is a senior endocrinologist and Head of the Neuroendocrine Tumors Service at Sheba Medical Center. He specializes in neuroendocrine tumors (NETs).

His work centers on hereditary NET syndromes. He is affiliated with the NIH in MEN1 research. He serves on an international VHL expert panel and helped write VHL management guidelines. He is the primary contact at Sheba’s multidisciplinary VHL clinic.

He leads the Endocrine Oncology Bioinformatics Lab. He collaborates with international teams, including the Weizmann Institute. He provides advanced NET care, including PRRT.

He earned his MD from the Hebrew University–Hadassah. He completed a residency at Assaf HaRofeh, an endocrinology fellowship at Rabin, and training at the NIH. He is board-certified in Endocrinology. He is a member of the Israeli Society of Endocrinology, the Endocrine Society, and the European Neuroendocrine Tumor Society. He has authored over 40 peer-reviewed papers, including in JAMA, Gastroenterology, and Radiology.

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Dr. Zohar Dotan is Head of the Urology Department at Sheba Medical Center. He is a leading uro-oncologist and a pioneer of robotic and laparoscopic urologic surgery in Israel.

He has authored more than 50 scientific publications. He is a regular speaker at international conferences. He has received awards from the American Association of Clinical Surgery, including recognition for research in prostate cancer treatment.

Leadership and credentials: Head of the Israeli Uro-Oncology Society. Assistant Professor at Tel Aviv University. Member of the Israeli, American, and European Urological Associations. Training: MD from Tel Aviv University and a PhD in Genetics. Urology residency at Sheba Medical Center. Fellowship in uro-oncology and laparoscopic surgery at Memorial Sloan Kettering, New York.

Dr. Nir Kleinmann, MD, directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is an expert in minimally invasive urology and urologic oncology. His focus is the kidney and upper urinary tract. He was named among Israel’s Best Doctors for 2025–2026 by Forbes and ResultMed.

He is a pioneer of kidney‑sparing laser surgery. He uses a dual‑laser system with neodymium and holmium for complex tumors. His expertise includes UTUC, kidney and prostate cancer, kidney stones, and BPH.

His research includes the OLYMPUS trial on chemoablation for UTUC. He has more than 60 publications.

He is an Israeli board‑certified urologist. He is a Fellow of the American Endourology Society and a member of the Israeli Urological Association and the EAU. He completed fellowships in Endourology and Minimally Invasive Surgery at Thomas Jefferson University. He also completed a fellowship in Kidney Cancer Research at McMaster University.

Prof. Gil Raviv, MD, PhD, is Director of the Andrology Unit at Sheba Medical Center. He was listed among the Best Doctors in Israel by Forbes in 2024. He is a leading expert in male fertility, sexual medicine, and reconstructive urology.

His primary focus is male infertility and fertility preservation. He performs advanced semen analysis according to WHO standards. He carries out testicular sperm retrieval (TESE, TESA, MESA) and semen cryopreservation. He also provides comprehensive fertility diagnostics with histological analysis.

He is a Professor at Tel Aviv University. He trained in Siena, Rome, and Tel Aviv. He completed a fellowship in infertility and impotence at Erasme Hospital. He received advanced training in reconstructive urethral surgery in Ghent. He is a member of the European Association of Urology, the International Society for Sexual Medicine, and the Israeli Urological Association.

Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.

Dr. Boaz Liberman

MD | Orthopedic Surgeon | Orthopedic Oncology & Sarcoma Specialist (Adult & Pediatric)

Department:

Orthopedic Surgery, Sheba Medical Center

Languages:

Hebrew, English

Professional Summary

Dr. Boaz Liberman is a leading orthopedic surgeon specializing in orthopedic oncology, with expertise in the treatment of bone and soft tissue sarcomas in both adult and pediatric patients. He serves as Director of the Orthopedic Oncology Unit and Vice Head of the Orthopedic Surgery Department at Sheba Medical Center.

Dr. Liberman focuses on combining oncologic surgery with advanced reconstructive techniques, aiming to preserve limb function and improve long-term outcomes across all age groups.

Areas of Expertise

Orthopedic oncology and sarcoma surgery (adult & pediatric)

Treatment of bone tumors and soft tissue sarcomas in children and adults

Reconstruction after bone metastases and tumor resection

Limb-sparing oncologic surgery

Revision joint replacement (revision arthroplasty)

Magnetic resonance-guided focused ultrasound (MRgFUS)

Complex joint reconstruction and prosthetic solutions

Education & International Training

MD, Sackler Faculty of Medicine, Tel Aviv University, Israel

Residency in Orthopedic Surgery, Sheba Medical Center

Fellowship in Adult Reconstruction Surgery, Mount Sinai Hospital, Toronto, Canada

Clinical Fellowship in Orthopedic Oncology Surgery, Mount Sinai Hospital & Princess Margaret Cancer Centre, Toronto, Canada

Clinical & Research Experience

Dr. Liberman treats a wide spectrum of oncologic orthopedic conditions in both children and adults, including complex primary tumors and metastatic bone disease.

His clinical approach focuses on:

limb preservation whenever clinically feasible

combining tumor resection with functional reconstruction

selecting personalized surgical strategies based on patient age, tumor type, and anatomy

He is also actively involved in research related to:

bone sarcoma biology and serum markers

innovative imaging-guided therapies

biomechanics of treated bone

Academic & Professional Roles

Director, Orthopedic Oncology Unit, Sheba Medical Center

Vice Head, Orthopedic Surgery Department

Clinical Instructor, Sackler Faculty of Medicine, Tel Aviv University

Member of:

Israel Medical Association

Israel Orthopedic Association

AATB (American Association of Tissue Banks)

EATB (European Association of Tissue Banks)

National advisory committees on tissue and organ transplantation

Board Certifications

Orthopedic Surgery

Orthopedic Oncology Surgery

Selected Publications

MRI arthrography and diagnostic correlation studies

Biomechanics of bone treated with MR-guided focused ultrasound

Additional peer-reviewed publications in orthopedic oncology

Why Patients Choose Dr. Liberman

Expertise in sarcoma treatment in both pediatric and adult patients

Strong focus on limb-sparing surgery and functional outcomes

Experience in complex oncologic and reconstructive procedures

International training in leading cancer centers

Dr. Eytan Aharon Ben-Ami, MD

Senior Physician, Sarcoma & Bone Oncology Service – Sheba Medical Center

Leading Expert in Sarcoma, Bone Tumors & Innovative Cancer Therapies

Dr. Eytan Ben-Ami is a highly specialized medical oncologist with extensive experience in the treatment of sarcomas and complex bone tumors, including rare and aggressive cancers.

As a senior physician at Sheba Medical Center, he plays a key role in delivering multidisciplinary, highly personalized care, often collaborating with pediatric and adult oncology teams to manage challenging soft tissue and bone malignancies.

Areas of Expertise

• Sarcoma (Core Expertise)
  Soft tissue sarcomas, liposarcoma, leiomyosarcoma, and rare tumor subtypes
•  
• Bone Oncology
  Osteosarcoma and other primary bone tumors
•  
• Advanced Medical Oncology
  • Targeted therapies and immunotherapy
  •  
  • Personalized treatment protocols for rare cancers
  •  
• Early-Phase Clinical Trials (Phase I)
  Access to innovative and next-generation cancer treatments

Clinical Leadership & Innovation

Dr. Ben-Ami is at the forefront of oncology innovation at Sheba, contributing to:

• Leadership in early-phase (Phase I) clinical trials, offering patients access to cutting-edge therapies
• Development of new treatment approaches for rare cancers
• Implementation of patient-centered innovations, including novel care delivery models

He also founded Sheba’s Clinical Research Organization (CRO), a pioneering initiative supporting advanced clinical research across multiple disciplines.

International Training & Expertise

Dr. Ben-Ami completed a prestigious fellowship in Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute / Harvard Cancer Center, one of the world’s leading cancer research institutions.

His approach combines:

• Global expertise in rare tumor management
• Advanced diagnostics and precision oncology
• Access to innovative therapies not widely available

Leadership & Academic Roles

• Senior Physician, Sarcoma & Bone Oncology Service, Sheba Medical Center
• Head of Oncology Division & Early-Phase Clinical Trials Unit
• Founder, Sheba Clinical Research Organization (CRO)
• Academic affiliation with Tel Aviv University

Research & Scientific Contribution

Dr. Ben-Ami is an active researcher with 40+ scientific publications, focusing on:

• Early detection and monitoring of sarcomas
• Molecular and viral mechanisms in rare tumors
• Development of innovative oncology treatments

He is also leading pilot programs in advanced immunotherapy delivery, improving accessibility and patient experience.

Clinical Approach

Dr. Ben-Ami is known for managing complex and rare cancer cases, offering:

• Highly individualized treatment strategies
• Multidisciplinary collaboration across oncology, surgery, and pediatrics
• Access to breakthrough therapies through clinical trials

Patient-Centered Care

Dr. Ben-Ami provides advanced, compassionate oncology care, combining cutting-edge science with a personalized approach, ensuring patients receive the most effective and innovative treatment options available.

A Leader in Rare Cancer Treatment

Through his expertise in sarcoma, bone oncology, and early-phase clinical research, Dr. Ben-Ami offers patients access to one of the most advanced programs globally for rare and complex cancers.